Page last updated: 2024-12-08
dihydrotestosterone heptanoate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dihydrotestosterone heptanoate: RN given refers to (5alpha,17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 160230 |
| SCHEMBL ID | 1317656 |
| MeSH ID | M0141952 |
Synonyms (15)
| Synonym |
|---|
| dhth |
| 33776-88-4 |
| [(5s,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] heptanoate |
| SCHEMBL1317656 |
| uaq3n36a25 , |
| dihydrotestosterone enanthate |
| dihydrotestosterone heptanoate |
| unii-uaq3n36a25 |
| androstan-3-one, 17-((1-oxoheptyl)oxy)-, (5alpha,17beta)- |
| 5.alpha.-androstan-3-one, 17.beta.-hydroxy-, heptanoate |
| stanolone enanthate |
| (5alpha,17beta)-17-[(1-oxoheptyl)oxy]androstan-3-one |
| androstanolone heptanoate |
| Q27290985 |
| DTXSID90955358 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Mean half-life estimates of the terminal elimination phase were 4 and 7 days for testosterone-enanthate and dihydrotestosterone-enanthate, respectively." | ( Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. Behre, HM; Jackwerth, B; Nieschlag, E; Weinbauer, GF; Yeung, CH; Yoon, YD, 1990) | 0.28 |
| " Receptor binding and pharmacokinetic data indicate that unesterified DHT is the active principle." | ( Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function. Eberle, AJ; Greger, NG; Keenan, BS; Panko, WB; Sparrow, JT, 1987) | 1.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.47
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||